Cancer is one of the biggest killers, and currently there are few ways to predict and improve patient outcomes. It has been shown that through the microbiome you can determine which patients will respond to therapies, and by manipulating it you can improve the efficacy of drugs. There is the potential to improve current therapies simply through altering the microbiome.
The Cancer Microbiome Congress (Boston, USA, 8-9 May 2018) will bring together academics, physicians, senior pharma executives and biotechs to learn about the developments and network to improve treatments in future. The speakers for the congress David Cook from Seres Therapeutics, the first company to develop live microbial therapeutics and Vancheswaran "Deepak" Gopalakrishnan from MD Anderson who published the groundbreaking paper identifying how the gut microbiome influences responses to Anti-PD1-Therapy.
For more information and registration visit: oncobiomecongressusa.com
